Bonnie Ky

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Faculty Member, Cardiovascular Institute, University of Pennsylvania School of Medicine
Faculty Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Attending Physician, Hospital of the University of Pennsylvania, Cardiology Consult and/or CCU service, 1-2 inpatient blocks/yr.
Director, Penn Center for Quantitative Echocardiography
Member, Abramson Cancer Center
Department: Medicine

Contact information
Hospital of the University of Pennsylvania
11-105 Smilow Center for Translational Research
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-573-6606
Fax: 215-746-7415
BS (Chemical Engineering )
Massachusetts Institute of Technology, 1995.
MD (Medicine)
University of Pennsylvania, 2001.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2009.
Permanent link

Description of Itmat Expertise

neuregulin signaling, endothelial growth factor signaling, cancer therapy cardiotoxicity, cardiac remodeling, echocardiography

Description of Research Expertise

My research interests are in translational cardiovascular epidemiology with a focus on the study of novel signaling pathways and mechanisms in human heart failure, cardiac remodeling, and cancer therapy cardiotoxicity. Current areas of research include:

1) Neuregulin Signaling:
We are interested in defining the relevance of circulating neuregulin as it relates to human heart failure and cardiac remodeling. I am the principal investigator of a longitudinal study determining the association between circulating neuregulin levels and cardiac remodeling and clinical outcomes in the Penn Heart Failure Study and the Chronic Renal Insufficiency Cohort.

2) Mechanistic Biomarker Studies in Cancer Therapy Cardiotoxicity:
We are interested in defining novel circulating biomarkers and genetic variations predictive of cancer therapy cardiotoxicity. Our objective is to gain mechanistic and translational insight into the pathophysiology of this disease. We have ongoing studies in specific pathways and biomarkers of interest, as well as proteomics discovery across various cardiotoxic regimens.

3) Myocardial Mechanics in Cancer Therapy Cardiotoxicity and Heart Failure:
We are interested in gaining insight into alterations in myocardial mechanics and sensitive measures of cardiac function, as defined by echocardiography, in patients exposed to cardiotoxic chemotherapy regimens as well as patients with chronic heart failure.

Selected Publications

French B, Wang L, Ky B, Fang JC, Sweitzer NK, Cappola TP. : Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. Journal of Cardiac Failure October 2015 Notes: Provisional Acceptance, October 2015.

Armenian SH, Xu L, Ky B, Sun C, Farol L, Pal S, Douglas PS, Bhatia S, Chao C. : Late Occurring Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community Based Retrospective Study. Journal of Clinical Oncology October 2015 Notes: Provisional Acceptance, October 2015.

Narayan HK, Khan AM, French B, Plappert T, Hyman D, Bajulaiye A, DeMichele A, Domchek S, Clark A, Fox K, Matro J, Bradbury A, Carver JR, Ky B.: Echocardiography-Derived Measures of Myocardial Mechanics Predict Cardiotoxicity with Breast Cancer Therapy. Journal of the American College of Cardiology Imaging. Journal of the American College of Cardiology Imaging October 2015 Notes: Provisional Acceptance, October 2015.

St. John Sutton, M. Cerkvenik J, Borlaug BA, Daubert C, Gold MR, Ghio S, Linde C, Ky B: The Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE). Journal of the American Heart Association 4(9), Sep 2015 Notes: Accepted for publication July 2015.

Putt ME, Hahn Shalkey V, Sawaya H, French B, Sebag I, Plana JC, Januzzi JL, Tan TC, Cohen V, Banchs J, Carver J, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M, Ky B. : Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clinical Chemistry July 2015 Notes: epub ahead of print.

Tchou J, Lam L, Li YR, Edwards C, Ky B, Zhang H: Monitoring Serum HER2 Levels in Breast Cancer Patients. Springer Plus Breast Cancer Collection 4(237), May 2015 Notes: doi: 10.1186/s40064-015-1015-6.

Haas, N Manola J, Ky B, Flaherty K, Uzzo RG, Kane CJ, Jewett M, Wood CG, Atkin MB, Dutcher JJ, DiPaolo RS: Effects of Sorafenib and Sunitinib on Cardiac Function in a Population without Overt Metastases: Cardiac Sub-study of a Phase III Trial of Sunitinib or Sorafenib or Placebo in Patients with High Risk Resected Renal Cell Carcinoma (E2805). Clinical Cancer Research May 2015.

Grandin E, Ky B, Cornell RF, Carver J, Lenihan DJ: Patterns of Cardiac Toxicity Associated with Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma. Journal of Cardiac Failure Page: doi: 10.1016/j.cardfail.2014.11.008, November 2014 Notes: epub ahead of print.

Vorovich E, French B, Ky B, Fang JC, Sweitzer NK, Cappola TP: Biomarker Predictors of Recurrent Cardiac Hospitalization in Chronic Heart Failure. Journal of Cardiac Failure 20(8): 569-76, August 2014.

St John Sutton M, Ky B, Regner SR, Schadt K, Plappert T, D'Souza B, Lynch DR: Longitudinal Strain in Friedreich Ataxia: A Potential Marker for Early Left Ventricular Dysfunction. Echocardiography 31(1): 50-57, August 2014 Notes: epub 2013.

back to top
Last updated: 10/27/2015
The Trustees of the University of Pennsylvania